[HTML][HTML] Niraparib in patients with newly diagnosed advanced ovarian cancer
…, AF Haggerty, MJ Rubio-Pérez… - … England Journal of …, 2019 - Mass Medical Soc
Background Niraparib, an inhibitor of poly (adenosine diphosphate [ADP]–ribose)
polymerase (PARP), has been associated with significantly increased progression-free …
polymerase (PARP), has been associated with significantly increased progression-free …
LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov …
…, F Heitz, L Gladieff, MJ Rubio-Pérez… - Annals of …, 2021 - annalsofoncology.org
Background OReO/ENGOT Ov-38 (NCT03106987), a randomized, double-blind trial, is the
first Phase III study to evaluate PARPi maintenance rechallenge. Methods Pts had non …
first Phase III study to evaluate PARPi maintenance rechallenge. Methods Pts had non …
[HTML][HTML] Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free …
…, PA Fasching, G Scambia, MJ Rubio-Pérez… - European Journal of …, 2022 - Elsevier
Abstract Background PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant
progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus …
progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus …
[HTML][HTML] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary …
A Poveda, S Lheureux, N Colombo, D Cibula… - Gynecologic …, 2022 - Elsevier
Abstract Objective The phase IIIb OPINION trial (NCT03402841) investigated olaparib
maintenance monotherapy in patients without a deleterious or suspected deleterious …
maintenance monotherapy in patients without a deleterious or suspected deleterious …
[HTML][HTML] INOVATYON/ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum …
…, G Tasca, B Pardo, G Tognon, MJ Rubio-Pérez… - British journal of …, 2023 - nature.com
Background This trial investigated the hypothesis that the treatment with trabectedin/PLD
(TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients …
(TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients …
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed …
…, A Okamoto, A Reuss, JW Kim, MJ Rubio-Pérez… - 2023 - ascopubs.org
LBA5506 Background: Olaparib (ola) maintenance (mtx) improved outcomes in pts with
newly diagnosed AOC and a BRCAm (DiSilvestro J Clin Oncol 2023; 41: 609–17) or with …
newly diagnosed AOC and a BRCAm (DiSilvestro J Clin Oncol 2023; 41: 609–17) or with …
DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and …
…, M Bidziński, N Colombo, A Floquet, MJ Rubio Pérez… - 2019 - ascopubs.org
TPS5598 Background: Ovarian cancer (OC) is the leading cause of death from gynecologic
cancers in US women. Despite high response rates to first-line treatment,~ 70% of patients …
cancers in US women. Despite high response rates to first-line treatment,~ 70% of patients …
[HTML][HTML] SEOM-GEICO clinical guidelines on endometrial cancer (2021)
…, I Romero, A Santaballa, MJ Rubio-Pérez - Clinical and …, 2022 - Springer
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide,
the first in developed countries [Sung et al. in CA Cancer J Clin 71: 209–249, 2021] …
the first in developed countries [Sung et al. in CA Cancer J Clin 71: 209–249, 2021] …
[HTML][HTML] Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) …
…, C Zamagni, F Heitz, L Gladieff, MJ Rubio-Pérez… - Annals of …, 2023 - Elsevier
Background Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the
standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy …
standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy …
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease …
…, N de Gregorio, AM Mosconi, MJ Rubio-Pérez… - 2023 - ascopubs.org
5550 Background: In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), maintenance ola (a
PARP inhibitor)+ bevacizumab (bev) led to prolonged progression-free and overall survival …
PARP inhibitor)+ bevacizumab (bev) led to prolonged progression-free and overall survival …